Geneventiv Therapeutics Inc. has been awarded a Direct to Phase II Small Business Innovation Research (SBIR) grant for approximately $2.5 million from the National Heart Lung Blood Institute (NHLBI) at the National Institutes of Health (NIH) to support development of a universal gene therapy for hemophilia A or B with or without inhibitors.
Basilea Pharmaceutica Ltd. has been awarded a grant from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) to support initial preclinical activities on the antibiotics program recently acquired from Spexis.
Lamassu Bio Inc. has been awarded a $2.05 million grant from the NIH and National Cancer Institute (NCI) for the development of SA-53 as a treatment for p53 wild-type sarcomas. SA-53 is designed to trigger the body’s natural defense mechanism p53 by blocking MDM2, a protein that deactivates p53 and contributes to treatment resistance.
The Department of Defense (DoD) office of the Congressionally Directed Medical Research Programs (CDMRP) has awarded funding to Biosplice Therapeutics Inc.’s collaboration with The Roskamp Institute aimed at developing novel therapies for traumatic brain injury (TBI).
CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) has announced an award of $1.06 million to the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) to develop a new class of small-molecule inhibitors of bacterial sliding clamp (DnaN), a pivotal component of DNA replication machinery, which is a clinically unproven but promising novel mechanism for targeting bacteria.
The National Institute of Neurological Disorders and Stroke (NINDS) has awarded a 3-year grant totaling approximately $4.1 million to the Research Institute at Nationwide Children’s Hospital to fund completion of preclinical studies, manufacturing and preparation of an IND application for a first-in-human trial to advance adeno-associated virus (AAV)-ATP7A gene therapy for the treatment of Menkes disease.
Children’s Hospital Los Angeles (CHLA) has received a multiyear $6 million award from the California Institute for Regenerative Medicine (CIRM) to develop innovative stem cell approaches to treat children and adolescents with recurrent solid tumors. The CIRM funding will support further CHLA research into harnessing chimeric antigen receptor (CAR) T-cell therapy.
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is awarding Glyprovac LLC US$467,000 to develop a maternal vaccine that targets Escherichia coli, a bacterial species responsible for a large portion of neonatal sepsis infections.
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), led by Boston University, is awarding $1.2 million to the Andrew G. Myers Research Group at Harvard University to develop a series of enhanced oral antibiotics that directly target a range of antibiotic-resistant bacteria which cause serious lower respiratory tract and skin and soft tissue infections.
RSS
